PIM
LOGC

Platinum Investment Management’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Platinum Investment Management’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-320,273
Closed -$740K – 150
2021
Q4 		$740K Hold
320,273
– – 0.02% 115
2021
Q3 		$1.47M Buy
+320,273
New +$1.41M 0.04% 111

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Platinum Investment Management's LOGC Position: Q1 2022 in Review

Platinum Investment Management sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q1 2022, closing a stake of 320,273 shares — an estimated $740K sold.

Platinum Investment Management first reported a position in LOGC in Q3 2021 and held it in 2 quarters. The position peaked at $1.47M in Q3 2021. 46 funds tracked by Wall St. Rank hold LOGC as of Q1 2022.

  • Platinum Investment Management reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Platinum Investment Management sold 320,273 LogicBio Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $740K.
  • Platinum Investment Management first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • Platinum Investment Management's LogicBio Therapeutics, Inc. Common Stock position peaked at $1.47M in Q3 2021.
  • 46 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Platinum Investment Management's 13F filing for Q1 2022, filed 13 May 2022.